acalabrutinib
astrazeneca
['acalabrutinib', 'lymsm']
acalabrutinib plus br leads to high cr rates in treatment-naive, relapsed/refractory mcl #eha2023 #lymsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.